Children’s is a nationally recognized leader in pediatric cancer diagnosis and treatment, and the Division of Hematology/Oncology and Bone Marrow Transplant provides the pediatric cancer care for the SCCA. The dedicated pediatric specialists in our 33-bed SCCA inpatient unit care for more than 240 new patients each year. Our multidisciplinary approach to treatment offers real advantages to our patients.
A diverse group of experienced pediatric specialists, present in one location and focused on the care of children, is able to deliver the best possible treatments. Members of our team include oncologists, surgeons, midlevel practitioners, nurses, nutritionists, social workers and child life specialists working in inpatient and outpatient settings. The Hematology/Oncology Clinic offers multiple specialty services, including a bone tumor clinic, bone marrow transplant services, hematologic and sickle cell disease clinics, a multidisciplinary solid tumor oncology clinic, a neuro-oncology clinic, surgical oncology care, palliative care and radiation therapy.
Whenever possible, we treat our patients with the Children’s Oncology Group protocols approved by our review board, which include investigational therapy or drugs when there are no effective standard therapies for a given diagnosis. We offer long-term follow-up through the ACCESS (After Cancer Care Ends, Survivorship Starts) Program, which helps pediatric cancer survivors live healthy lives, and through the Long-Term Follow-up Program, which evaluates effects after hematopoietic cell transplant. Based on our overall dedication to improving survival rates for children with brain tumors, the depth of our program, the clinical resources of our institution and our ability to perform innovative research, Children’s was one of nine institutions in the United States selected for membership in the Pediatric Brain Tumor Consortium.
Our research activities to improve cancer treatment encompass internationally recognized programs at Children’s, the University of Washington and FHCRC. These activities have been responsible for the development of widely used clinical treatments, including hematopoietic stem cell transplantation and a novel targeted therapy for treating acute myelogenous leukemia.